Alexis Ji, Ph.D.
Venture Partner at Illumina Ventures
Dr. Alexis Ji joined Illumina Ventures as a partner since its founding in 2016. Alexis brings 20 years of experience in life science R&D and venture investment in the biopharmaceutical and genomics industries. She focuses on building pioneering early-stage companies that bring disruptive science or technologies into novel therapies, research tools or diagnostics. Alexis currently serves on the board of Walking Fish Therapeutics, Actym Therapeutics, NanoCellect Biomedical, and a stealth mode company, and she previously observed on the board of Twist Bioscience (Nasdaq: TWST) and SQZ Biotechnologies (NYSE: SQZ).
Prior to Illumina Ventures, Alexis was a principal at WuXi Healthcare Ventures, responsible for venture investment in the US, where she was instrumental in the investment in Twist Bioscience, 23andme, Juno Therapeutics, Unity Biotechnology, Vivace Therapeutics, Ideaya Therapeutics, and Medeor Therapeutics, among other companies. Before WuXi, Alexis was an investment consultant at ARCH Venture Partners, where she evaluated early-stage investment opportunities, including the founding investment in Twist Bioscience, and backed portfolio companies’ operations.
Alexis started her career in biotechnology R&D, in early drug discovery at Merck, translational research and clinical development at Roche, and molecular diagnostics and next-generation sequencing at Life Technologies.
Alexis earned her Ph.D. in Molecular Genetics from Washington University School of Medicine, an MBA from University of Chicago Booth School of Business, and a Bachelor in Biochemistry from Shandong University.